[go: up one dir, main page]

HRP20150462T1 - Derivat 1,2,4-triazolona - Google Patents

Derivat 1,2,4-triazolona Download PDF

Info

Publication number
HRP20150462T1
HRP20150462T1 HRP20150462TT HRP20150462T HRP20150462T1 HR P20150462 T1 HRP20150462 T1 HR P20150462T1 HR P20150462T T HRP20150462T T HR P20150462TT HR P20150462 T HRP20150462 T HR P20150462T HR P20150462 T1 HRP20150462 T1 HR P20150462T1
Authority
HR
Croatia
Prior art keywords
oxo
dihydro
acetamide
ethyl
triazol
Prior art date
Application number
HRP20150462TT
Other languages
English (en)
Inventor
Takeshi Kuwada
Mitsukane Yoshinaga
Tomoko Ishizaka
Daisuke Wakasugi
Shin-Ichi Shirokawa
Nobutaka Hattori
Youichi Shimazaki
Naoki Miyakoshi
Original Assignee
Taisho Pharmaceutical Co., Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taisho Pharmaceutical Co., Ltd filed Critical Taisho Pharmaceutical Co., Ltd
Publication of HRP20150462T1 publication Critical patent/HRP20150462T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C07D451/06—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Claims (13)

1. Derivat 1,2,4-triazolona prikazan s Formulom (1A): [image] u Formuli (1A), R1 predstavlja C1-5 alkil proizvoljno supstituiran s jednom do tri skupine odabrane iz skupine koju čine hidroksi, halogeni atomi, cijano, C3-7 cikloalkil, i C1-5 alkoksi; C3-7 cikloalkil, ili 4- do 8-člani zasićeni heterocikal; R2 predstavlja atom vodika ili C1-5 alkil; R3 predstavlja aril ili heteroaril proizvoljno supstituiran s jednom ili dvije skupine odabrane iz skupine koju čine C1-5 alkoksi, C1-5 alkil, halogeni atomi, trifluorometil, trifluorometoksi, cijano, hidroksi, difluorometoksi, i C1-5 alkilsulfonil; R4 i R5 mogu biti isti ili različiti i svaki predstavlja atom vodika, C1-5 alkil proizvoljno supstituiran s jednom do tri skupine odabrane iz skupine koju čine hidroksi, halogeni atomi, cijano, C3-7 cikloalkil, i C1-5 alkoksi; C3-7 cikloalkil, ili 4- do 8-člani zasićeni ili nezasićeni heterocikal koji u prstenu sadrži jedan ili više atoma dušika, kisika, ili sumpora proizvoljno supstituiran s jednom ili dvije skupine odabrane iz skupine koju čine hidroksi, C1-5 alkil, C1-5 alkoksi, halogeni atomi, cijano, C2-5 alkanoil, te trifluorometil; ili R4 i R5 proizvoljno, zajedno sa susjednim dušikovim atomom, tvore 4- do 8-člani zasićeni ili nezasićeni heterocikal koji proizvoljno u prstenu sadrži jedan ili više atoma dušika, kisika, ili sumpora, pored susjednog dušikovog atoma, u prstenu proizvoljno supstituiran s jednom ili dvije skupine odabrane iz skupine koju čine hidroksi, C1-5 alkil proizvoljno supstituiran s jednim ili dva hidroksi; C1-5 alkoksi, halogenim atomima, cijano, C2-5 alkanoil, okso, aminokarbonilom, mono-C1-5 alkilaminokarbonilom, di-C1-5 alkilaminokarbonilom, trifluorometilom, i amino proizvoljno supstituiran s jednom ili dvije skupine odabrane iz skupine koju čine C1-5 alkil i C2-5 alkanoil; i 4- do 8-člani zasićeni ili nezasićeni heterocikal koji proizvoljno ima C1-5 alkilensku skupinu koja unakrsno povezuje dva različita atoma ugljika u prstenu ili tvore 2-oksa-6-azaspiro[3.3]hept-6-il ili 7-oksa-2-azaspiro[3.5]non-2-il; A predstavlja fenilen ili 6-člani heteroarilen proizvoljno supstituiran s jednim ili dvije skupine odabrane od halogenih atoma i C1-5 alkoksi; X predstavlja jednostruku vezu, -O-, ili -NR6-; R6 predstavlja atom vodika, C1-5 alkil, ili C2-5 alkanoil; Ra predstavlja atom vodika ili C1-5 alkil; i n je cijeli broj od 0 do 3, ili farmaceutski prihvatljiva sol derivata 1,2,4-triazolona.
2. Derivat 1,2,4-triazolona ili njegova farmaceutski prihvatljiva sol prema zahtjevu 1 naznačen time da R4 i R5 mogu biti isti ili različiti i svaki predstavlja atom vodika, C1-5 alkil proizvoljno supstituiran s jednom do tri skupine odabrane iz skupine koju čine hidroksi, halogeni atomi, cijano, C3-7 cikloalkil, i C1-5 alkoksi; C3-7 cikloalkil, ili 4- do 8-člani zasićeni ili nezasićeni heterocikal koji u prstenu sadrži jedan ili više atoma dušika, kisika, ili sumpora proizvoljno supstituiran s jednom ili dvije skupine odabrane iz skupine koju čine hidroksi, C1-5 alkil, C1-5 alkoksi, halogeni atomi, cijano, C2-5 alkanoil, i trifluorometil; ili R4 i R5 proizvoljno, zajedno sa susjednim dušikovim atomom, tvore 4- do 8-člani zasićeni ili nezasićeni heterocikal koji proizvoljno u prstenu sadrži jedan ili više atoma dušika, kisika, ili sumpora, pored susjednog dušikovog atoma, proizvoljno supstituiran s jednom ili dvije skupine odabrane iz skupine koju čine hidroksi, C1-5 alkil proizvoljno supstituiran s jednim ili dva hidroksi; C1-5 alkoksi, halogenim atomima, cijano, C2-5 alkanoil, okso, aminokarbonilom, mono-C1-5 alkilaminokarbonilom, di-C1-5 alkilaminokarbonilom, i trifluorometilom, te 4- do 8-članim zasićenim ili nezasićenim heterociklom koji proizvoljno ima C1-5 alkilensku skupinu koja unakrsno povezuje dva različita atoma ugljika u prstenu) ili tvori 2-oksa-6-azaspiro[3.3]hept-6-il; i n je cijeli broj od 1 do 3.
3. Derivat 1,2,4-triazolona ili njegova farmaceutski prihvatljiva sol prema zahtjevu1 naznačen time da R3 predstavlja aril ili heteroaril proizvoljno supstituiran s jednom ili dvije skupine odabrane iz skupine koju čine C1-5 alkoksi, C1-5 alkil, halogeni atomi, trifluorometil, trifluorometoksi, cijano, hidroksi, i difluorometoksi; R4 i R5 mogu biti isti ili različiti i svaki predstavlja atom vodika, C1-5 alkil proizvoljno supstituiran s jednom do tri skupine odabrane iz skupine koju čine hidroksi, halogeni atomi, cijano, C3-7 cikloalkil, i C1-5 alkoksi; C3-7 cikloalkil, ili 4- do 8-člani zasićeni ili nezasićeni heterocikal koji u prstenu sadrži jedan ili više atoma dušika, kisika, ili sumpora proizvoljno supstituiran s jednom ili dvije skupine odabrane iz skupine koju čine hidroksi, C1-5 alkil, C1-5 alkoksi, halogeni atomi, cijano, C2-5 alkanoil, te trifluorometil; ili R4 i R5 proizvoljno, zajedno sa susjednim dušikovim atomom, tvore 4- do 8-člani zasićeni ili nezasićeni heterocikal koji proizvoljno u prstenu sadrži jedan ili više atoma dušika, kisika, ili sumpora, pored susjednog dušikovog atoma, proizvoljno supstituiran s jednom ili dvije skupine odabrane iz skupine koju čine hidroksi; C1-5 alkil proizvoljno supstituiran s jednim ili dva hidroksi; C1-5 alkoksi, halogenim atomima, cijano, C2-5 alkanoil, okso, aminokarbonilom, mono-C1-5 alkilaminokarbonilom, di-C1-5 alkilaminokarbonil, i trifluorometilom, te 4- do 8-članim zasićenim ili nezasićenim heterociklom koji proizvoljno ima C1-5 alkilensku skupinu koja unakrsno povezuje dva različita atoma ugljika u prstenu; ili tvori 2-oksa-6-azaspiro[3.3]hept-6-il; A predstavlja fenilen ili 6-člani heteroarilen; Ra predstavlja atom vodika; i n je cijeli broj od 1 do 3.
4. Derivat 1,2,4-triazolona ili njegova farmaceutski prihvatljiva sol prema bilo kojem zahtjevu od 1 do 3, naznačen time da R1 je C1-5 alkil; R2 je atom vodika; i R3 je fenil ili piridil proizvoljno supstituiran s jednom ili dvije skupine odabrane iz skupine koju čine C1-5 alkil, C1-5 alkoksi, halogeni atomi, cijano, hidroksi, trifluorometil, difluorometoksi, i trifluorometoksi.
5. Derivat 1,2,4-triazolona ili njegova farmaceutski prihvatljiva sol prema bilo kojem zahtjevu od 1 do 4, naznačen time da A je fenilen, piridindiil, ili pirimidindiil proizvoljno supstituiran s jednom ili dvije skupine odabrane od halogenih atoma i C1-5 alkoksi.
6. Derivat 1,2,4-triazolona ili njegova farmaceutski prihvatljiva sol prema bilo kojem zahtjevu od 1 do 4, naznačen time da A je fenilen ili piridindiil proizvoljno supstituiran s jednom ili dvije skupine odabrane od halogenih atoma i C1-5 alkoksi.
7. Derivat 1,2,4-triazolona ili njegova farmaceutski prihvatljiva sol prema zahtjevu 6, naznačen time da A predstavlja bilo koju od Formula (2) do (4): [image]
8. Derivat 1,2,4-triazolona ili njegova farmaceutski prihvatljiva sol prema bilo kojem zahtjevu od 1 do 7, naznačen time da X je jednostruka veza; n je cijeli broj 1; te R4 i R5 proizvoljno, zajedno sa susjednim dušikovim atomom, tvore 4- do 8-člani zasićeni ili nezasićeni heterocikal koji proizvoljno u prstenu sadrži jedan ili više atoma dušika, kisika, ili sumpora, pored susjednog dušikovog atoma, proizvoljno supstituiran s jednom ili dvije skupine odabrane iz skupine koju čine hidroksi, C1-5 alkil proizvoljno supstituiran s jednim ili dva hidroksi; C1-5 alkoksi, halogenim atomima, cijano, C2-5 alkanoil, okso, aminokarbonilom, mono-C1-5 alkilaminokarbonil, di-C1-5 alkilaminokarbonil, i trifluorometil, i 4- do 8-članim zasićenim ili nezasićenim heterociklom koji proizvoljno ima C1-5 alkilensku skupinu koja unakrsno povezuje dva različita atoma ugljika u prstenu; ili tvore 2-oksa-6-azaspiro[3.3]hept-6-il.
9. Derivat 1,2,4-triazolona ili njegova farmaceutski prihvatljiva sol prema bilo kojem zahtjevu od 1 do 8, naznačen time da R4 i R5, zajedno sa susjednim dušikovim atomom, tvore 5- ili 6-člani zasićeni heterocikal koji proizvoljno u prstenu sadrži jedan ili više atoma dušika, kisika, ili sumpora, pored susjednog dušikovog atoma, proizvoljno supstituiran s jednom ili dvije skupine odabrane iz skupine koju čine hidroksi i C1-5 alkil, i 5- ili 6-člani zasićeni heterocikal koji proizvoljno ima C1-5 alkilensku skupinu koja unakrsno povezuje dva različita atoma ugljika u prstenu; ili tvore 2-oksa-6-azaspiro[3.3]hept-6-il.
10. Derivat 1,2,4-triazolona ili njegova farmaceutski prihvatljiva sol prema bilo kojem zahtjevu od 1 do 8, naznačen time da R4 i R5, zajedno sa susjednim dušikovim atomom, tvore 6-člani zasićeni heterocikal koji proizvoljno sadrži jedan ili više atoma kisika, pored susjednog dušikovog atoma, u prstenu proizvoljno supstituiran s jednim ili dva hidroksi, te 6-člani zasićeni heterocikal koji proizvoljno ima C1-5 alkilensku skupinu koja unakrsno povezuje dva različita atoma ugljika u prstenu; ili tvore 2-oksa-6-azaspiro[3.3]hept-6-il.
11. Jedna tvar, ili smjesa dvije ili više tvari naznačena time da su odabrane iz skupine koja sadrži slijedeće spojeve i njihove farmaceutski prihvatljive soli prema zahtjevu 1: 2-[3-(3-klorofenil)-1-{4-[2-(morfolin-4-il)etil]fenil}-5-okso-1,5-dihidro-4H-1,2,4-triazol-4-il]-N-(propan-2-il)acetamid, 2-[3-(3-klorofenil)-1-{4-[2-(3-hidroksipirolidin-1-il)etil]fenil}-5-okso-1,5-dihidro-4H-1,2,4-triazol-4-il]-N-(propan-2-il)acetamid, 2-[3-(3-klorofenil)-1-(4-{2-[3-(hidroksimetil)pirolidin-1-il]etil}fenil)-5-okso-1,5-dihidro-4H-1,2,4-triazol-4-il]-N-(propan-2-il)acetamid, 2-[3-(3-klorofenil)-1-{4-[2-(3-hidroksi-8-azabiciklo[3.2.1]okt-8-il)etil]fenil -5-okso-1,5-dihidro-4H-1,2,4-triazol-4-il]-N-(propan-2-il)acetamid, 2-[3-(3-klorofenil)-1-{4-[2-(8-oksa-3-azabiciklo[3.2.]okt-3-il)etil]fenil}-5-okso-1,5-dihidro-4H-1,2,4-triazol-4-il]-N-(propan-2-il)acetamid, 2-[3-(3-klorofenil)-1-{4-[2-(3-oksa-8-azabiciklo[3.2.1]okt-8-il)etil]fenil}-5-okso-1,5-dihidro-4H-1,2,4-triazol-4-il]-N-(propan-2-il)acetamid, 2-[3-(3-klorofenil)-5-okso-1-{4-[2-(piperidin-1-il)etil]fenil}-1,5-dihidro-4H-1,2,4-triazol-4-il]-N-(propan-2-il)acetamid, 2-[3-(3-klorofenil)-1-{4-[2-(1,4-oksazepan-4-il)etil]fenil}-5-okso-1,5-dihidro-4H-1,2,4-triazol-4-il]-N-(propan-2-il)acetamid, 2-[3-(3-klorofenil)-1-{5-[2-(morfolin-4-il)etil]piridin-2-il}-5-okso-1,5-dihidro-4H-1,2,4-triazol-4-il]-N-(propan-2-il)acetamid, 2-[3-(3-klorofenil)-1-{5-[2-(3-hidroksi-8-azabiciklo[3.2.1]okt-8-il)etil]piridin-2-il}-5-okso-1,5-dihidro-4H-1,2,4-triazol-4-il]-N-(propan-2-il)acetamid, 2-[3-(3-klorofenil)-1-{5-[2-(3-oksa-8-azabiciklo[3.2.1]okt-8-il)etil]piridin-2-il}-5-okso-1,5-dihidro-4H-1,2,4-triazol-4-il]-N-(propan-2-il)acetamid, 2-[3-(3-klorofenil)-1-{6-[2-(morfolin-4-il)etil]piridin-3-il}-5-okso-1,5-dihidro-4H-1,2,4-triazol-4-il]-N-(propan-2-il)acetamid, N-tert-butil-2-[3-(3-klorofenil)-1-{4-[2-(morfolin-4-il)etil]fenil}-5-okso-1,5-dihidro-4H-1,2,4-triazol-4-il]acetamid, 2-[3-(3-klorofenil)-1-{4-[2-(morfolin-4-il)etil]fenil}-5-okso-1,5-dihidro-4H-1,2,4-triazol-4-il]-N-(1,1,1-trifluoropropan-2-il)acetamid, 2-[3-(3-klorofenil)-1-{4-[2-(morfolin-4-il)etil]fenil}-5-okso-1,5-dihidro-4H-1,2,4-triazol-4-il]-N-(1-hidroksi-2-metilpropan-2-il)acetamid, 2-[3-(3-klorofenil)-1-{4-[2-(morfolin-4-il)etil]fenil}-5-okso-1,5-dihidro-4H-1,2,4-triazol-4-il]-N-ciklobutilacetamid, 2-[3-(3-klorofenil)-1-{4-[2-(morfolin-4-il)etil]fenil}-5-okso-1,5-dihidro-4H-1,2,4-triazol-4-il]-N-(oksetan-3-il)acetamid, 2-[3-(3-klorofenil)-1-{4-[2-(morfolin-4-il)etil]fenil}-5-okso-1,5-dihidro-4H-1,2,4-triazol-4-il]-N-(ciklopropilmetil)acetamid, 2-[3-(3-metoksifenil)-1-{4-[2-(morfolin-4-il)etil]fenil}-5-okso-1,5-dihidro-4H-1,2,4-triazol-4-il]-N-(propan-2-il)acetamid, 2-[3-(4-fluoro-3-metoksifenil)-5-okso-1-{4-[2-(piperidin-1-il)etil]fenil}-1,5-dihidro-4H-1,2,4-triazol-4-il]-N-(propan-2-il)acetamid, 2-[3-(4-fluoro-3-metoksifenil)-1-{4-[2-(morfolin-4-il)etil]fenil}-5-okso-1,5-dihidro-4H-1,2,4-triazol-4-il]-N-(propan-2-il)acetamid, 2-[3-(4-fluoro-3-metoksifenil)-1-{4-[2-(3-hidroksi-8-azabiciklo[3.2.1]okt-8-il)etil]fenil}-5-okso-1,5-dihidro-4H-1,2,4-triazol-4-il]-N-(propan-2-il)acetamid, 2-[3-(4-fluoro-3-metoksifenil)-1-{4-[2-(3-oksa-8-azabiciklo[3.2.1]okt-8-il)etil]fenil}-5-okso-1,5-dihidro-4H-1,2,4-triazol-4-il]-N-(propan-2-il)acetamid, 2-[3-(4-fluoro-3-metoksifenil)-1-{5-[2-(morfolin-4-il)etil]piridin-2-il-5-okso-1,5-dihidro-4H-1,2,4-triazol-4-il]-N-(propan-2-il)acetamid, 2-[3-(4-fluoro-3-metoksifenil)-1-{5-[2-(3-hidroksi-8-azabiciklo[3.2.1]okt-8-il)etil]piridin-2-il}-5-okso-1,5-dihidro-4H-1,2,4-triazol-4-il]-N-(propan-2-il)acetamid, 2-[3-(4-fluoro-3-metoksifenil)-1-{5-[2-(3-oksa-8-azabiciklo[3.2.1]okt-8-il)etil]piridin-2-il}-5-okso-1,5-dihidro-4H-1,2,4-triazol-4-il]-N-(propan-2-il)acetamid, 2-[3-(3-kloro-4-fluorofenil)-5-okso-1-{4-[2-(piperidin-1-il)etil]fenil}-1,5-dihidro-4H-1,2,4-triazol-4-il]-N-(propan-2-il)acetamid, 2-[3-(3-kloro-4-fluorofenil)-1-{4-[2-(morfolin-4-il)etil]fenil}-5-okso-1,5-dihidro-4H-1,2,4-triazol-4-il]-N-(propan-2-il)acetamid, 2-[3-(3-kloro-4-fluorofenil)-1-{4-[2-(2-oksa-6-azaspiro[3.3]hept-6-il)etil]fenil}-5-okso-1,5-dihidro-4H-1,2,4-triazol-4-il]-N-(propan-2-il)acetamid, 2-[3-(3-kloro-4-fluorofenil)-1-{4-[2-(1,4-oksazepan-4-il)etil]fenil}-5-okso-1,5-dihidro-4H-1,2,4-triazol-4-il]-N-(propan-2-il)acetamid, 2-[3-(3-kloro-4-fluorofenil)-1-{4-[2-(3-oksa-8-azabiciklo[3.2.]okt-8-il)etil]fenil}-5-okso-1,5-dihidro-4H-1,2,4-triazol-4-il]-N-(propan-2-il)acetamid, 2-[3-(3-kloro-4-fluorofenil)-1-{4-[2-(3-hidroksi-8-azabiciklo[3.2.1]okt-8-il)etil]fenil}-5-okso-1,5-dihidro-4H-1,2,4-triazol-4-il]-N-(propan-2-il)acetamid, 2-[3-(3-kloro-4-fluorofenil)-5-okso-1-{5-[2-(piperidin-1-il)etil]piridin-2-il}-1,5-dihidro-4H-1,2,4-triazol-4-il]-N-(propan-2-il)acetamid, 2-[3-(3-kloro-4-fluorofenil)-1-{5-[2-(morfolin-4-il)etil]piridin-2-il}-5-okso-1,5-dihidro-4H-1,2,4-triazol-4-il]-N-(propan-2-il)acetamid, 2-[3-(3-kloro-4-fluorofenil)-1-{5-[2-(2-oksa-6-azaspiro[3.3]hept-6-il)etil]piridin-2-il}-5-okso-1,5-dihidro-4H-1,2,4-triazol-4-il]-N-(propan-2-il)acetamid, 2-[3-(3-kloro-4-fluorofenil)-1-{5-[2-(3-oksa-8-azabiciklo[3.2.1]okt-8-il)etil]piridin-2-il}-5-okso-1,5-dihidro-4H-1,2,4-triazol-4-il]-N-(propan-2-il)acetamid, 2-[3-(3-cijanofenil)-1-{4-[2-(morfolin-4-il)etil]fenil}-5-okso-1,5-dihidro-4H-1,2,4-triazol-4-il]-N-(propan-2-il)acetamid, 2-[3-(3-fluorofenil)-1-{4-[2-(morfolin-4-il)etil]fenil}-5-okso-1,5-dihidro-4H-1,2,4-triazol-4-il]-N-(propan-2-il)acetamid, 2-(1-{4-[2-(morfolin-4-il)etil]fenil}-5-okso-3-fenil-1,5-dihidro-4H-1,2,4-triazol-4-il)-N-(propan-2-il)acetamid, 2-[3-(3-klorofenil)-1-{3-fluoro-4-[2-(morfolin-4-il)etil]fenil}-5-okso-1,5-dihidro-4H-1,2,4-triazol-4-il]-N-(propan-2-il)acetamid, 2-[3-(3-klorofenil)-1-{3-fluoro-4-[2-(3-oksa-8-azabiciklo[3.2.]okt-8-il)etil]fenil}-5-okso-1,5-dihidro-4H-1,2,4-triazol-4-il]-N-(propan-2-il)acetamid, 2-[3-(3-klorofenil)-1-{3-metoksi-4-[2-(morfolin-4-il)etil]fenil}-5-okso-1,5-dihidro-4H-1,2,4-triazol-4-il]-N-(propan-2-il)acetamid, 2-[3-(3-klorofenil)-1-{3-metoksi-4-[2-(3-oksa-8-azabiciklo[3.2.1]okt-8-il)etil]fenil}-5-okso-1,5-dihidro-4H-1,2,4-triazol-4-il]-N-(propan-2-il)acetamid, 2-[3-(3-klorofenil)-1-{4-[2-(morfolin-4-il)propil]fenil}-5-okso-1,5-dihidro-4H-1,2,4-triazol-4-il]-N-(propan-2-il)acetamid, 2-[3-(3-klorofenil)-1-{4-[2-(3-oksa-8-azabiciklo[3.2.1]okt-8-il)propil]fenil}-5-okso-1,5-dihidro-4H-1,2,4-triazol-4-il]-N-(propan-2-il)acetamid, 2-[3-(3-klorofenil)-1-{5-[2-(morfolin-4-il)propil]piridin-2-il}-5-okso-1,5-dihidro-4H-1,2,4-triazol-4-il]-N-(propan-2-il)acetamid, 2-[3-(3-klorofenil)-1-{5-[2-(3-oksa-8-azabiciklo[3.2.]okt-8-il)propil]piridin-2-il}-5-okso-1,5-dihidro-4H-1,2,4-triazol-4-il]-N-(propan-2-il)acetamid, N-tert-butil-2-[3-(3-klorofenil)-1-{5-[2-(morfolin-4-il)etil]piridin-2-il}-5-okso-1,5-dihidro-4H-1,2,4-triazol-4-il]acetamid, N-tert-butil-2-[3-(3-klorofenil)-1-{5-[2-(3-oksa-8-azabiciklo[3.2.1]okt-8-il)etil]piridin-2-il}-5-okso-1,5-dihidro-4H-1,2,4-triazol-4-il]acetamid, 2-[3-(3-metoksifenil)-1-{4-[2-(3-oksa-8-azabiciklo[3.2.1]okt-8-il)etil]fenil}-5-okso-1,5-dihidro-4H-1,2,4-triazol-4-il]-N-(propan-2-il)acetamid, N-tert-butil-2-[3-(3-metoksifenil)-1-{5-[2-(morfolin-4-il)etil]piridin-2-il}-5-okso-1,5-dihidro-4H-1,2,4-triazol-4-il]acetamid, N-tert-butil-2-[3-(3-metoksifenil)-1-{5-[2-(3-oksa-8-azabiciklo[3.2.1]okt-8-il)etil]piridin-2-il}-5-okso-1,5-dihidro-4H-1,2,4-triazol-4-il]acetamid, 2-[3-(2-bromo-5-klorofenil)-1-{4-[2-(morfolin-4-il)etil]fenil}-5-okso-1,5-dihidro-4H-1,2,4-triazol-4-il]-N-(propan-2-il)acetamid, 2-(3-[3-(metilsulfonil)fenil]-1-{4-[2-(morfolin-4-il)etil]fenil}-5-okso-1,5-dihidro-4H-1,2,4-triazol-4-il)-N-(propan-2-il)acetamid, 2-[3-(3-klorofenil)-1-{4-[2-(morfolin-4-il)etil]fenil}-5-okso-1,5-dihidro-4H-1,2,4-triazol-4-il]-N-(propan-2-il)acetamid, (+)-2-[3-(3-klorofenil)-1-{5-[2-(3-oksa-8-azabiciklo[3.2.1]okt-8-il)propil]piridin-2-il -5-okso-1,5-dihidro-4H-1,2,4-triazol-4-il]-N-(propan-2-il)acetamid, (-)-2-[3-(3-klorofenil)-1-{5-[2-(3-oksa-8-azabiciklo[3.2.1]okt-8-il)propil]piridin-2-il}-5-okso-1,5-dihidro-4H-1,2,4-triazol-4-il]-N-(propan-2-il)acetamid, 2-[3-(4-fluoro-3-metoksifenil)-1-{4-[2-(3-oksa-8-azabiciklo[3.2.1]okt-8-il)propil]fenil}-5-okso-1,5-dihidro-4H-1,2,4-triazol-4-il]-N-(propan-2-il)acetamid, 2-[3-(4-fluoro-3-metoksifenil)-1-{5-[2-(3-oksa-8-azabiciklo[3.2.1]okt-8-il)propil]piridin-2-il}-5-okso-1,5-dihidro-4H-1,2,4-triazol-4-il]-N-(propan-2-il)acetamid, N-tert-butil-2-[3-(3-metoksifenil)-1-{4-[2-(3-oksa-8-azabiciklo[3.2.1]okt-8-il)propil]fenil}-5-okso-1,5-dihidro-4H-1,2,4-triazol-4-il]acetamid, N-tert-butil-2-[3-(3-metoksifenil)-1-{5-[2-(3-oksa-8-azabiciklo[3.2.1]okt-8-il)propil]piridin-2-il}-5-okso-1,5-dihidro-4H-1,2,4-triazol-4-il]acetamid, 2-[3-(6-metoksipiridin-2-il)-1-{4-[2-(morfolin-4-il)etil]fenil}-5-okso-1,5-dihidro-4H-1,2,4-triazol-4-il]-N-(propan-2-il)acetamid, i 2-[3-(6-metoksipiridin-2-il)-1-{4-[2-(3-oksa-8-azabiciklo[3.2.1]okt-8-il)etil]fenil}-5-okso-1,5-dihidro-4H-1,2,4-triazol-4-il]-N-(propan-2-il)acetamid.
12. Farmaceutski pripravak naznačen time da kao aktivni sastojak sadrži derivat 1,2,4-triazolona ili njegovu farmaceutski prihvatljivu sol prema bilo kojem zahtjevu od 1 do 11.
13. Derivat 1,2,4-triazolona ili njegova farmaceutski prihvatljiva sol prema bilo kojem zahtjevu od 1 do 11 naznačen time da je za uporabu u sprječavanju ili liječenju poremećaja raspoloženja, anksioznosti, shizofrenije, Alzheimerove bolesti, Parkinsonove bolesti, Huntingtonove koreje, poremećaja prehrane, hipertenzije, gastrointestinalne bolesti, ovisnost o drogama, epilepsije, cerebralne infarkcije, cerebralna ishemije, cerebralnog edema, ozljede glave, upale, imunološki povezane bolesti, ili alopecije.
HRP20150462TT 2010-10-01 2015-04-29 Derivat 1,2,4-triazolona HRP20150462T1 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2010224233 2010-10-01
JP2011054500 2011-03-11
EP20110829344 EP2623499B1 (en) 2010-10-01 2011-09-30 1,2,4-triazolone derivative
PCT/JP2011/072556 WO2012043791A1 (ja) 2010-10-01 2011-09-30 １，２，４-トリアゾロン誘導体

Publications (1)

Publication Number Publication Date
HRP20150462T1 true HRP20150462T1 (hr) 2015-07-17

Family

ID=45893228

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20150462TT HRP20150462T1 (hr) 2010-10-01 2015-04-29 Derivat 1,2,4-triazolona

Country Status (30)

Country Link
US (1) US9193695B2 (hr)
EP (1) EP2623499B1 (hr)
JP (1) JP5787237B2 (hr)
KR (1) KR101820185B1 (hr)
CN (1) CN103119028B (hr)
AU (1) AU2011308403B2 (hr)
BR (1) BR112013007389B1 (hr)
CA (1) CA2811192C (hr)
CY (1) CY1116518T1 (hr)
DK (1) DK2623499T3 (hr)
ES (1) ES2536084T3 (hr)
HK (1) HK1182109A1 (hr)
HR (1) HRP20150462T1 (hr)
HU (1) HUE025729T2 (hr)
IL (1) IL225091A (hr)
ME (1) ME02169B (hr)
MX (1) MX2013003633A (hr)
MY (1) MY165626A (hr)
NZ (1) NZ608729A (hr)
PH (1) PH12013500571A1 (hr)
PL (1) PL2623499T3 (hr)
PT (1) PT2623499E (hr)
RS (1) RS54112B1 (hr)
RU (1) RU2566754C2 (hr)
SG (1) SG189156A1 (hr)
SI (1) SI2623499T1 (hr)
SM (1) SMT201500166B (hr)
TW (1) TWI518075B (hr)
WO (1) WO2012043791A1 (hr)
ZA (1) ZA201302651B (hr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2853227C (en) 2011-10-27 2019-05-14 Taisho Pharmaceutical Co., Ltd. Azole derivative
JP5929812B2 (ja) * 2012-03-30 2016-06-08 大正製薬株式会社 １，２，４−トリアゾロン誘導体を含有する医薬
TWI568722B (zh) * 2012-06-15 2017-02-01 葛蘭馬克製藥公司 作爲ｍＰＧＥＳ－１抑制劑之三唑酮化合物
US9730447B2 (en) 2013-04-15 2017-08-15 E I Du Pont De Nemours And Company Fungicidal amides
JP6387669B2 (ja) * 2013-04-26 2018-09-12 大正製薬株式会社 アゾール誘導体を含有する医薬
US9988367B2 (en) * 2016-05-03 2018-06-05 Bayer Pharma Aktiengesellschaft Amide-substituted pyridinyltriazole derivatives and uses thereof
US10800746B2 (en) * 2016-05-03 2020-10-13 Bayer Pharma Aktiengesellschaft Oxoalkyl-substituted phenyltriazole derivatives and uses thereof

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2076257A1 (en) * 1991-09-13 1993-03-14 Jan Heeres 4-¬4-¬4-(4-hydroxyphenyl)-1- piperazinyl|phenyl|-5-methyl-3h -1,2,4-triazol-3-one derivatives
JP2000063363A (ja) * 1998-08-12 2000-02-29 Yamanouchi Pharmaceut Co Ltd 新規なトリアゾール誘導体
FR2792314B1 (fr) * 1999-04-15 2001-06-01 Adir Nouveaux composes aminotriazoles, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2804114B1 (fr) 2000-01-25 2002-03-08 Sanofi Synthelabo Nouveaux derives de 1,3-dihydro-2h-indol-2-one, un procede pour leur preparation et les compositions pharmaceutiques en contenant
US6710049B2 (en) * 2000-12-26 2004-03-23 Ranbaxy Laboratories Limited Azole compounds as anti-fungal agents
AU2003288640A1 (en) * 2002-12-31 2004-07-22 Pfizer Products Inc. Benzamide inhibitors of the p2x7 receptor
CN101279971A (zh) * 2003-04-28 2008-10-08 安斯泰来制药有限公司 4,4－二氟－1,2,3,4－四氢－5h－1－苯并氮杂䓬衍生物或其盐
EP1659121A4 (en) 2003-08-28 2008-11-26 Taisho Pharmaceutical Co Ltd 1,3-dihydro-2H-indol-2-one derivative
US20050070718A1 (en) 2003-09-30 2005-03-31 Abbott Gmbh & Co. Kg Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
GB0329693D0 (en) * 2003-12-22 2004-01-28 Pfizer Ltd Compounds useful in therapy
US7745630B2 (en) 2003-12-22 2010-06-29 Justin Stephen Bryans Triazolyl piperidine arginine vasopressin receptor modulators
AP2331A (en) * 2003-12-22 2011-12-05 Pfizer Triazole derivatives as vasopressin antagonists.
US7902369B2 (en) * 2004-03-05 2011-03-08 Banyu Pharmaceutical Co., Ltd. Diaryl-substituted five-membered heterocycle derivative
NZ549396A (en) 2004-03-26 2010-04-30 Hoffmann La Roche Tetrahydrocarbazoles and derivatives
BRPI0510340A (pt) * 2004-04-28 2007-10-30 Pfizer derivados de 3-heterociclil-4-feniltriazol como inibidores do receptor via da vasopressina
AR052342A1 (es) * 2004-12-21 2007-03-14 Janssen Pharmaceutica Nv Derivados sustituidos de triazolona,tetrazolona e imidazolona con actividad selectiva antagonista de alfa2c-adenoreceptores
TW200643015A (en) 2005-03-11 2006-12-16 Akzo Nobel Nv 2-(4-oxo-4H-quinazolin-3-yl)acetamide derivatives
JP2008534504A (ja) 2005-03-22 2008-08-28 アゼヴァン ファーマスーティカルズ，インコーポレイテッド 月経前障害を治療するためのβラクタミルアルカン酸
WO2006133242A2 (en) 2005-06-07 2006-12-14 Pharmacopeia, Inc. Azinone and diazinone v3 inhibitors for depression and stress disorders
WO2007109098A2 (en) 2006-03-16 2007-09-27 Azevan Pharmaceuticals, Inc. HYDROXY AND KETO-SUBSTITUTED β-LACTAMYL ALKANEDIOIC ACIDS
RU2430095C2 (ru) * 2006-03-24 2011-09-27 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Производное триазолона
DE102006024024A1 (de) 2006-05-23 2007-11-29 Bayer Healthcare Aktiengesellschaft Substituierte Arylimidazolone und -triazolone sowie ihre Verwendung
WO2008025736A1 (en) 2006-08-26 2008-03-06 Abbott Gmbh & Co. Kg Substituted benzimidazolone derivatives, medicaments comprising them and their use
WO2008033764A2 (en) 2006-09-11 2008-03-20 N.V. Organon Quinazolinone and isoquinolinone acetamide derivatives
CA2663193A1 (en) 2006-09-11 2008-03-20 N.V. Organon 2-(1-oxo-1h-isoquinolin-2-yl)acetamide derivatives
DE102007002715A1 (de) * 2007-01-18 2008-07-24 Merck Patent Gmbh Triazolderivat
JP2010229035A (ja) 2007-08-01 2010-10-14 Taisho Pharmaceutical Co Ltd ピリドピリミジン−４−オン誘導体
GB2454290B (en) * 2007-08-07 2009-09-30 Prosarix Ltd Novel serotonergic modulators
WO2009130231A1 (en) 2008-04-24 2009-10-29 Glaxo Group Limited Pyrrolo [1, 2-a] pyrazine derivatives as vasopressin vib receptor antagonists
WO2009130232A1 (en) * 2008-04-24 2009-10-29 Glaxo Group Limited Pyrazolo [1, 5 -a] pyrazine derivatives as antagonists of v1b receptors
JP5369721B2 (ja) 2009-01-30 2013-12-18 大正製薬株式会社 ピリドピリミジン−４−オン誘導体
DE102009013642A1 (de) * 2009-03-18 2010-09-23 Bayer Schering Pharma Aktiengesellschaft Substituierte Phenylalaninderivate und deren Verwendung
JP2013075830A (ja) 2010-02-03 2013-04-25 Taisho Pharmaceutical Co Ltd キノリン誘導体
WO2011104322A1 (de) 2010-02-27 2011-09-01 Bayer Pharma Aktiengesellschaft Bis-arylverknüpfte aryltriazolone und ihre verwendung
CA2853227C (en) * 2011-10-27 2019-05-14 Taisho Pharmaceutical Co., Ltd. Azole derivative

Also Published As

Publication number Publication date
TW201307303A (zh) 2013-02-16
ZA201302651B (en) 2014-06-25
MX2013003633A (es) 2013-04-24
CN103119028B (zh) 2016-05-25
SG189156A1 (en) 2013-05-31
ME02169B (me) 2015-10-20
NZ608729A (en) 2014-08-29
RU2013120338A (ru) 2014-11-20
JPWO2012043791A1 (ja) 2014-02-24
WO2012043791A1 (ja) 2012-04-05
TWI518075B (zh) 2016-01-21
MY165626A (en) 2018-04-18
EP2623499A4 (en) 2014-06-25
AU2011308403B2 (en) 2014-08-21
AU2011308403A1 (en) 2013-04-18
SI2623499T1 (sl) 2015-10-30
CN103119028A (zh) 2013-05-22
BR112013007389A2 (pt) 2017-11-21
BR112013007389B1 (pt) 2022-03-22
EP2623499B1 (en) 2015-04-22
CA2811192A1 (en) 2012-04-05
US9193695B2 (en) 2015-11-24
US20130197217A1 (en) 2013-08-01
CA2811192C (en) 2018-02-27
ES2536084T3 (es) 2015-05-20
KR101820185B1 (ko) 2018-01-18
HUE025729T2 (en) 2016-04-28
JP5787237B2 (ja) 2015-09-30
EP2623499A1 (en) 2013-08-07
DK2623499T3 (da) 2015-06-08
RU2566754C2 (ru) 2015-10-27
CY1116518T1 (el) 2017-03-15
KR20140000669A (ko) 2014-01-03
PT2623499E (pt) 2015-05-21
HK1182109A1 (zh) 2013-11-22
SMT201500166B (it) 2015-09-07
RS54112B1 (en) 2015-12-31
IL225091A (en) 2016-09-29
PL2623499T3 (pl) 2015-09-30
PH12013500571A1 (en) 2013-06-10

Similar Documents

Publication Publication Date Title
HRP20150462T1 (hr) Derivat 1,2,4-triazolona
HRP20201469T1 (hr) Derivati tetrahidroizokinolina
HRP20160421T1 (hr) Derivat azola
ES2629414T3 (es) Derivados de tiazol
JP2017530185A5 (hr)
HRP20171670T1 (hr) Spojevi i sastavi za moduliranje egfr-aktiviteta
ES2688548T3 (es) Compuestos aza bicíclicos como agonistas del receptor muscarínico M1
JP2014506599A5 (hr)
JP2019517596A5 (hr)
AU2005260821B2 (en) Fused benzamide compound and vanilloid receptor 1 (VR1) activity inhibitor
IL277183B2 (en) Bicyclic compounds as inhibitors of pd1/pd-l1 interaction/activation
JP2016517878A5 (hr)
BR122023020853A2 (pt) Compostos 2-amino-n-heteroaril-nicotinamidas, composição farmacêutica que os compreende e usos dos mesmos
CN111201223A (zh) SHP2的八氢环戊二烯并[c]吡咯别构抑制剂
HRP20210447T1 (hr) Piridinski spoj
RU2018112237A (ru) Новые бициклические соединения в качестве дуальных ингибиторов atx/ca
HRP20180382T1 (hr) Inhibitori protein kinaze
HRP20171913T1 (hr) Aminopirimidinilni spojevi kao inhibitori jak
RU2013145299A (ru) Тиазолопиримидины
BR112016010041A2 (pt) composto, medicamento, e, uso do composto ou sal
HRP20161797T1 (hr) Spojevi 1,3-oksazolidina ili 1,3-oksazinana kao antagonisti receptora oreksina
HRP20220096T1 (hr) Inhibitori lizin specifične demetilaze-1
JP2016528212A (ja) 複素芳香環−ベンジル−アミド−サイクルコアを含むオートタキシン阻害剤
IL295076B1 (en) Piperidinone derivatives as MDM2 inhibitors for cancer treatment
TWI816704B (zh) 苯并咪唑衍生物及其用途